Depression & Antidepressants Fareed Bhatti Pennine VTS - November 2009.

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

Depression Lawrence Pike.
Depression and HIV Patient
DEPRESSION and ANXIETY
Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.
GENERALIZED ANXIETY DISORDER IN PRIMARY CARE Curley Bonds, MD Medical Director Didi Hirsch Mental Health Services Professor & Chair Charles R. Drew University.
Depression Alison Turner-Parry Sam Rosenburg. Aims  To have an enjoyable time covering elements of the GP mental health curriculum.
Mood disorders ( affective disorders ) prof. MUDr. Eva Češková, CSc. Dept. of Psychiatry, Dept. of Psychiatry, Masaryk University, Brno Masaryk University,
Treating Depression in the Primary Care Setting Pharmacologic Interventions Presented by: Jonathan Betlinski, MD Date: 09/25/2014.
NICE guidelines update 2013 Katie Simpson South Central SHA IAPT GP Clinical Lead Mental Health Lead Berks East PCT.
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Mood Disorders. Level of analysis Depression as a symptom Depression as a syndrome Depression as a disorder.
Chapter 14 Depressive Disorders
TYPES OF MENTAL ILLNESS. OVERVIEW DEPRESSION ANXIETY SUBSTANCE ABUSE.
EPECEPECEPECEPEC EPECEPECEPECEPEC Depression, Anxiety, Delirium Depression, Anxiety, Delirium Module 6 The Project to Educate Physicians on End-of-life.
Clinical Knowledge Summaries CKS Depression
Claudia L. Reardon, MD Assistant Professor University of Wisconsin School of Medicine and Public Health NAMI Wisconsin Annual Meeting April 24, 2015.
Dr Maryam Naeem GPST2 Psychiatry
2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.
Depression Ibrahim Sales, Pharm.D. Associate Professor of Clinical Pharmacy King Saud University
Drugs used in affective disorders: antidepressants
National Institute for Health and Clinical Excellence (NICE) Clinical Guideline on Depression & Anxiety  We understand how much of GP’s time is spent.
+ Bipolar Disorder Dajshone Bruce Psychology, period 3 May 1,2011.
CLINICAL PATHWAYS: DEPRESSION
An introduction to IAPT Richard Thwaites - First Step Clinical Lead May 2013.
Clinical Knowledge Summaries (CKS) Depression
Major Depressive Disorder Presenting Complaints
SSRIs & Antidepressants
Depression in Norway By Jørgen and Philip.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Mood Disorders. Major Depressive Disorder  Five or more symptoms present for two weeks or more:  Disturbed Mood  depressed mood  anhedonia (reduced.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
Chapter 7 Mood Disorders and Suicide
Depression Rebecca Sposato MS, RN. Depression  An episode lasting over two weeks marked by depressed mood or inability to feel enjoyment  Very common.
Major Depressive Disorder Natalie Gomez Psychology Period 1.
IzBen C. Williams, MD, MPH Instructor. Lecture - 8 MOOD DISORDERS.
DEPRESSION Dr.Jwaher A.Al-nouh Dr.Eman Abahussain
Basics of outpatient depression management Chris Zamani MD.
Strategies to Switch Antidepressants Brittany Parmentier, PharmD PGY2 Behavioral Care Resident Butler University/Community Health Network This speaker.
Depression Key slides. What is depression? NICE Full guideline CG90. October 2009.
Mood Disorders: Depression Chapter 12. Defined as a depressed mood or loss of interest that lasts at least 2 weeks & is accompanied by symptoms such as.
B ENZODIAZEPINE DEPENDENCE. WHO - ICD 10 C RITERIA FOR S UBSTANCE D EPENDENCE A definite diagnosis of dependence syndrome should usually be made only.
Depressive Disorders and Substance Use Disorders.
Depressive Illness and Antidepressants
Bipolar Disorder and Substance Use Disorders Bipolar I Disorder Includes one or more Manic Episodes or Mixed Episodes, sometimes with Major Depressive.
Implementing NICE guidance 2011 NICE clinical guideline 113 Generalised anxiety disorder in adults.
THE PHILIPPINE COLLEGE OF PSYCHOPHARMACOLOGY 2008 MAJOR DEPRESSION (Featuring the LAPEL method) TEACHING MODULE FOR THE PRIMARY CARE PHYSICIANS.
Depression Dr. Alan Ng Behavioural Medicine. Reference Psychiatry in Primary Care Editors: Goldbloom, Davine CAMH, Toronto 2011.
Psychosocial issues for the diabetic patient 2010 Diabetes Area Workshop Fiona Little-CNC Mental Health.
IN THE NAME OF GOD MOOD DISORDERS MOHAMAD NADI M.D PSYCHIATRIST.
Depression Management Presentation 1 of 3 Documented diagnosis PHQ tool Depression care assessment.
DR.JAWAHER A. AL-NOUH K.S.U.F.PSYCH. Depression. Introduction: Mood is a pervasive and sustained feeling tone that is experienced internally and that.
DEPRESSION & CHRONIC ILLNESS Robert Postlethwaite Clinical Psychologist.
CHAPTER 16 Mood Disorders. Mood Mood can be defined as a pervasive and sustained emotion or feeling tone that influences a persons behavior and colours.
Chapter Depression Barbour, Hoffman, and Blumenthal C H A P T E R.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Case study Which antidepressant Dr. Matthew Miller.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Depression & Common Mental Health Problems. Persistent sadness Tiredness Loss of Interest Agitation or slow movement Poor sleep Guilt or worthlessness.
NICE guidance Generalised Anxiety Disorder Alex Hill.
IN THE NAME OF GOD MOOD DISORDERS MOHAMAD NADI M.D PSYCHIATRIST.
Management of Depression in Adults Jon van Niekerk.
Treating generalised anxiety disorder in primary care – an example of a treatment pathway Step 3: review and consideration of alternative treatments Step.
Depression and Aging Aging Q 3 William P. Moran, MD, MS Medical University of South Carolina October 31, 2012.
PSY 436 Instructor: Emily Bullock Yowell, Ph.D.
Durham and Tees Valley VTS Sept 2017 Dr Rachel Lunney Dr Steven Rowan
Trimipramine – Summary of West Suffolk CCG and PrescQIPP Guidance
PHARMACOTHERAPY - I PHCY 310
PSY 436 Instructor: Emily E. Bullock, Ph.D.
Depression Lawrence Pike.
Presentation transcript:

Depression & Antidepressants Fareed Bhatti Pennine VTS - November 2009

Format of Presentation Split into subgroups ….. ( if possible) 3 presenters About minutes Covered Topics - New NICE guidelines for Depression(Oct 2009) - How to start, switching between antidepressants & stopping them. - Individual characteristics of Antidepressants - Antidepressants in Pregnancy Some AKT style questions (MCQs) thrown in somewhere….. Chocolates for right answers!

Why is it important? Worldwide lifetime incidence ~4-10% for major depression 2.5% and 5% for dysthymia ( chronic low grade symptoms) Numbers for UK ( King’s Fund report 2006): In million people with depression in England, By 2026 projected to rise by 17 % to 1.45 million. Costs:. In 2007 the total cost of services for depression in England ~ £1.7 billion with lost employment £7.5 billion. By 2026 cost ~ £3 billion & with lost employment £12.2 billion. QOF points ( ) = 53 for depression -DM/CVD pts screened for depression in past 15 months - 8 points -New diagnosis in past year- formal assessment(e.g.PHQ9 ) - 25 points -Re-evaluate using the same tool in 5-12 weeks - 20 points

Question 1 What are the two screening questions for depression in primary care? (Chocolates only for telling both!)

Answer 1. During the last month have you often been bothered by feeling down, depressed or hopeless? 2. During the last month, have you often been bothered by having little interest or pleasure in doing things?

Question 2 Name any 7 symptoms that you would use to assess for depression?

Answer Symptoms of general low mood include: sadness and tearfullness low self-esteem guilt pessimism helplessness hopelessness apathy loss of interests anhedonia loss of concentration depersonalisation Paranoia Anxiety symptoms of depression include: tension apprehension phobic disorders The somatic features of depression include: loss of appetite weight loss constipation insomnia or hypersomnia amenorrhoea low libido psychomotor retardation or agitation Psychotic symptoms (severe depression): hallucinations typically derogatory auditory hallucinations delusions e.g. delusions of worthlessness

Severities of Depression Subthreshold: < 5 symptoms. Mild Depression : Just above 5 with minor functional impairment. Moderate: Symptoms or functional impairment between mild and severe. Severe: Most symptoms, marked functional impairment.

New NICE Guidelines for Depression-Salient points 1.Assessment Principles-duration and severity with degree of impairment should also be considered. 2.Encompasses adults with chronic illnesses as well. 3.Sub threshold depression recognised and guidelines given. 4.Diagnostic criteria has been changed from ICD-10 to DSM-IV so psychosocial therapies can be matched to the illness more appropriately. 5.Clearer role of psychosocial interventions defined but implications for existing overstretched services. 6.More accountability for the psychosocial interventions. 7.Guidance for relapse prevention-talking therapies+ meds.

Treatment of Depression with Chronic Illness - High Intensity psychosocial intervention - SSRI - Combination of both Low Intensity psychosocial intervention Collaborative care between primary and secondary care for long term Rx and follow up Treatment of Persistent sub-threshold(PST) Depressive symptoms

Important difference from previous guidance:. Not routinely but can consider antidepressant for -Subthreshold depressive symptoms with past history of moderate or severe depression. -Mild depression that complicates care of physical health problem -Initial presentation of PST > 2 years -PST or mild depression persisting after other interventions

Stepped Care Model. Assessment & Support; Education. Active monitoring & referral for further assessments & interventions All known & suspected presentations of depression. Low intensity psychological & psychosocial interventions. Medication. Referral for further assessments & interventions. Persistent sub- threshold depression &. Mild to Moderate. Medication. High intensity psychosocial interventions. Combined treatments. Collaborative care. Referral. PST / Mild to Moderate with inadequate response to initial interventions. Moderate and Severe. Medication. High intensity psychosocial interventions. ECT. Crisis service. Admission. Combined Treatments. Severe and Complex depression. Risk to life.Severe self neglect

Psychosocial interventions Low-intensity psychosocial interventions Indications: For PST depressive symptoms or mild to moderate depression +/- chronic physical health problem, PST symptoms that complicate care of the chronic physical health problem Preventing relapse Types ( guided by the patient’s preference) – Structured group physical activity programme – Group-based peer support (self-help) programme – Individual guided self-help based on the principles of CBT – Computerised CBT -- Group based mindfulness –based CBT High-intensity psychological interventions Indications Treatment for moderate depression For patients with initial presentation of moderate depression and a chronic physical health Preventing relapse of depression –some cases Types -- Group-based CBT / Interpersonal therapy/ behavioural activation – Individual CBT or -- Behavioural couples therapy for selected patients

Starting antidepressants The consultation: - Give choice - Explore I,C &Es - Discuss no addiction potential - Shouldn't discontinue suddenly - Need to continue beyond remission - Safety netting and follow up. Follow up - <30yrs or high risk of suicide- see after 1 week and then frequently. - Less risk of suicide- see after 2 weeks then 2-4 weeks uptil 3 months then longer intervals. Should the antidepressants ever be put on patient’s repeat medication?

Drug titration -If SEs early on monitor& reassure OR stop and change OR upto 2 weeks addition of benzodiazepine (according to symptoms and not for chronic anxiety) weeks Minimal response check compliance & increase support OR increase dose OR switch antidepressant Some improvement Continue for another 2-4 weeks & change antidepressant if inadequate response, SEs or patient choice.

Choosing and changing antidepressants Choosing: - Patient choice -SSRIs - Generic SSRI 1 st line- consider PPI in elderly or if on aspirin/ NSAIDs etc. - Sertraline /Citalopram for people with chronic illnesses as lower interactions. - Higher interactions with Fluoxetine, Fluvoxamine and Paroxetine. - Paroxetine – higher discontinuation symptoms. -TCAs - Higher toxicity risk in overdose except Lofepramine, so increase dose slowly. - Dosulepin(TCA) –not recommended because of high risk of toxicity with OD. -MAO Inhibitors/ Lithium or lithium augmentation-Psychiatrists Changing: SSRI Different SSRI or better tolerated newer generation drug Venlafaxine TCAs Another class

To:TCATrazodone SSRI (Citalopram, Sertraline, Paroxetine) SSRI (Fluoxetine) MirtazapineReboxetineMoclobemideVenlafaxine From TCA Cross-taper cautiously Halve dosage and add trazodone, then slow withdrawal Halve dosage and add SSRI, then slow withdrawal Halve dosage and add fluoxetine, then slow withdrawal Cross-taper cautiously Withdraw and wait at least 1 week Cross-taper cautiously starting with venlafaxine 37.5 mg/day Trazodone Cross-taper cautiously with very low dosage of TCA — Withdraw, then start SSRI Withdraw, then start fluoxetine Cross taper cautiously Withdraw, start reboxetine at 2 mg twice a day and increase cautiously Withdraw and wait at least 1 week Withdraw. Start at venlafaxine at 37.5 mg/day SSRI (Citalopram, Sertraline, Paroxetine) Cross-taper cautiously Withdraw, then start trazodone — Withdraw, then start fluoxetine Cross-taper cautiously Withdraw and wait at least 2 weeks Withdraw. Start venlafaxine 37.5 mg/day and increase very slowly SSRI (Fluoxetine) Stop fluoxetine. Start TCA at very low dosage and increase very slowly Stop fluoxetine. Wait 4–7 days, then start low- dose trazodone Stop fluoxetine. Wait 4–7 days, then start SSRI at low dose* and increase slowly — Withdraw and start mirtazapine cautiously Withdraw, start reboxetine at 2 mg twice a day and increase cautiously Withdraw and wait at least 5 weeks Withdraw. Wait 4-7 days. Start venlafaxine at 37.5 mg/day. Increase very slowly Mirtazapine Withdraw, then start TCA Withdraw, then start trazodone Withdraw, then start SSRI Withdraw, then start fluoxetine — Withdraw, then start reboxetine Withdraw and wait for 1 week Withdraw, then start venlafaxine Reboxetine Cross-taper cautiously — Withdraw and wait at least 1 week Cross-taper cautiously Moclobemide Withdraw and wait 24 hours — TCA, tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitor. * Citalopram 10 mg/day; sertraline 25 mg/day; or paroxetine 10 mg/day.

Question 3 A 64 years old lady comes to see you 3 weeks after her husband’s death. You notice she looks depressed. She reports poor sleep, appetite, loss of pleasure in activities and feelings of depersonalisation. What would you suggest a)Sertraline. b)St John’s wort with light therapy. c)Bereavement counselling. d)Any combination of above.

Answer 3 Careful monitoring and Bereavement counselling. Although has a lot of features of depression and might very well develop into that, at present secondary to bereavement and therefore doesn’t qualify as true endogenous depression.

Stopping antidepressants & preventing relapse ▫Gradually reduce the dose over a 4 weeks, can be slower. Fluoxetine can usually be stopped over a shorter period(longer half life). ▫Some drugs like paroxetine and venlafaxine have a shorter half-life and more chances of discontinuation syndromes. (See GP notebook for table for reducing doses) ▫Discontinuation symptoms Management : - Mild = reassure and monitor. - Severe = reintroduction of original antidepressant at effective dose(or another antidepressant with a longer halflife) Started antidepressants Remission achieved Continue Meds for 6 more months same dose Significant risk of relapse OR Hx of Recurrent depression Significant risk of relapse OR Hx of Recurrent depression Continue meds for 2 years and then review Continue meds for 2 years and then review Thinking about stopping? - Is it recurrent illness - Any residual symptoms or - Continuing psychosocial /physical health problems Thinking about stopping? - Is it recurrent illness - Any residual symptoms or - Continuing psychosocial /physical health problems Augment meds if needed Psychological interventions- CBT or mindfulness based CBT

The End